News and Announcements

Today, March 27, 2025, Chemomab Therapeutics issued a press release announcing results from the Open Label Extension (OLE) section of the...

On February 19, 2025, Chemomab Therapeutics issued a press release announcing plans for a Phase 3 clinical trial for the treatment of PSC....

Three Recent Announcements from: Pliant, NGM, and Chemomab PSC Partners is encouraged by the initial positive data from the CM-101 Phase...

On July 15, 2024, Pliant Therapeutics announced positive results from their Phase 2a INTEGRIS-PSC trial for bexotegrast in treatment of...

The following is a message from Mirum Pharmaceuticals regarding their VISTAS study for volixibat, a possible new treatment for...

Exciting news about the Pliant Therapeutics PSC clinical trial preliminary results from their global INTEGRIS-PSC Phase 2a trial for...

News from the EASLCongress 2023 meeting in Vienna From the "late-breaking" abstract session on June 24, 2023, results of the pre-planned...

Statement From Gilead Sciences on September 27, 2022 Early Termination of Gilead-Sponsored Study GS-US-428-4194: A Phase 3, Randomized,...

A proof-of-concept Phase 2 trial conducted by Mayo Clinic and sponsored by Immunic has shown very early positive results. We hope that...

The clinical trials resources page has been updated on 1/27/21 to reflect two clinical trials currently recruiting. PLN 74809: Phase 2a...

Check out this video invitation from PSC nutrition study Principal Investigator Dr. Josh Korzenik to participate in a diet and nutrition...